Our Products in Europe

ABILIFY® (aripiprazole)

ABILIFY contains the active substance aripiprazole. It is available in different forms (tablets, oral solution and a solution for injection). ABILIFY is used in the treatment of schizophrenia and moderate to severe manic episodes in Bipolar I Disorder. If you are a healthcare professional and want to read more about ABILIFY, click here. If you are a patient or member of the general public and want information about ABILIFY, click here. To learn more about psychosis and schizophrenia, we recommend www.psykossjukdom.nu and Schizofreniskolan and to learn more about bipolar disorder we recommend Bipolärguiden.

Abilify Maintena® (aripiprazole)

Abilify Maintena contains the active substance aripiprazole. It is available as a powder and solvent to be made into a suspension for injection. It is used for the maintenance treatment of schizophrenia in adults whose disease has already been stabilised on treatment with oral aripiprazole. If you are a healthcare professional and want to read more about Abilify Maintena, click here. If you are a patient or member of the general public and want information about Abilify Maintena, click here. To learn more about psychosis and schizophrenia, we recommend www.psykossjukdom.nu and Schizofreniskolan.

Samsca® (tolvaptan)

Samsca contains the active substance tolvaptan. It is available as a tablet. Samsca is used to treat adults with hyponatraemia (abnormally low levels of sodium in the blood) caused by a condition called ‘syndrome of inappropriate antidiuretic-hormone secretion’ (SIADH). To read more about Samsca, click here.

JINARC®  (tolvaptan)

JINARC contains the active ingredient tolvaptan and it is available as a tablet. It is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease. If you are a healthcare professional and want to read more about JINARC, click here. If you are a patient or member of the general public and want information about JINARC click here. For more information about the disease ADPKD, we recommend you to click here to read more.

Pletal® (cilostazol)

Pletal contains the active substance cilostazol. It is available as a tablet. Pletal is indicated for the improvement of maximal and pain-free walking distances in patients with intermittent claudication, who do not have rest pain and who do not have evidence of peripheral tissue necrosis (peripheral arterial disease Fontaine stage II). You will find more information about Pletal here.

Adacolumn®

Medical device for leukocyte apheresis. Adacolumn is a medical device for the treatment of active inflammatory bowel disease (IBD). The treatment works through selective adsorption of leukocytes (selectively granulocytes and monocytes/macrophages) from the blood. You will find more information about Adacolumn here. For more information about Inflammatory Bowel Disease (Chrohns disease and Ulcerative cholitis), we recommend you to click here to read more. For more information about Otsuka’s global portfolio, please visit our global website. For information on products that are currently in the pipeline, please visit the Otsuka Holdings Co., Ltd. website

Date of preparation: November 2017

Reference OPSE/1017/COMS/1092

)